176 related articles for article (PubMed ID: 34755064)
1. Immune-related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis.
Imai S; Nakamura M; Chujo S; Ooki R; Inoue Y; Horiuchi H; Morikawa T; Uchino K; Igarashi A; Shiga Y
IJU Case Rep; 2021 Nov; 4(6):386-390. PubMed ID: 34755064
[TBL] [Abstract][Full Text] [Related]
2. Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib.
Nishimoto K; Shirotake S; Miyama Y; Kaneko G; Kanao K; Igarashi D; Takahashi T; Umezawa Y; Yasuda M; Oyama M
IJU Case Rep; 2022 May; 5(3):149-152. PubMed ID: 35509782
[TBL] [Abstract][Full Text] [Related]
3. A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib.
Kimura S; Fujisaki Y; Onizuka C; Hasuike S; Sato Y; Mukai S; Kamoto T
IJU Case Rep; 2023 Jul; 6(4):206-210. PubMed ID: 37405030
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases.
Tamada S; Ikarashi D; Tsuyukubo T; Iwasaki K; Isurugi K; Ono S; Takata R; Fujisawa H; Obara W
IJU Case Rep; 2022 Nov; 5(6):438-441. PubMed ID: 36341193
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date.
Chau V; Bilusic M
Cancer Manag Res; 2020; 12():7321-7330. PubMed ID: 32884346
[TBL] [Abstract][Full Text] [Related]
8. Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach.
Wood LS; Ornstein MC
JCO Oncol Pract; 2020 Feb; 16(2_suppl):15s-19s. PubMed ID: 32045538
[TBL] [Abstract][Full Text] [Related]
9. Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report.
Hanawa K; Sawada N; Aikawa J; Otake Y; Kasai Y; Mochizuki K; Shimura H; Mochizuki T; Kira S; Mitsui T
Oncol Lett; 2024 Feb; 27(2):66. PubMed ID: 38192652
[TBL] [Abstract][Full Text] [Related]
10. Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report.
Katsumata Y; Kawasaki Y; Tanaka K; Nakayama D; Katayama H; Shimada S; Satake Y; Sato T; Kawamorita N; Yamashita S; Sato T; Shoji K; Mitsuzuka K; Ito A
Case Rep Oncol; 2021; 14(3):1522-1529. PubMed ID: 34899246
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Watson TR; Gao X; Reynolds KL; Kong CY
JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
[TBL] [Abstract][Full Text] [Related]
12. Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy.
Yoshimura A; Yamamoto Y; Nishikawa T; Fujita M; Inoue T; Kondo F; Hayashi T; Kawamura N; Nagahara A; Nakai Y; Nakayama M; Nishimura K
Int Cancer Conf J; 2024 Jan; 13(1):26-32. PubMed ID: 38187183
[TBL] [Abstract][Full Text] [Related]
13. A case of an advanced renal collecting duct carcinoma in which initial therapeutic effect was achieved with pembrolizumab plus axitinib.
Atagi Y; Daizumoto K; Mohri S; Somiya K; Seto D; Nakanishi S; Yanagihara Y; Ninomiya I; Okamoto K; Yamashi S
IJU Case Rep; 2024 Jan; 7(1):50-55. PubMed ID: 38173448
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report.
Olsen TA; Martini DJ; Evans ST; Goldman JM; Bilen MA
J Med Case Rep; 2021 Feb; 15(1):72. PubMed ID: 33602288
[TBL] [Abstract][Full Text] [Related]
16. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
17. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus axitinib combination and the paradigm change in the treatment of advanced renal cell carcinoma.
Spisarová M; Melichar B; Vitásková D; Študentová H
Future Oncol; 2021 Jan; 17(3):241-254. PubMed ID: 33016119
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness Analysis of Pembrolizumab Plus Axitinib Versus Sunitinib in First-line Advanced Renal Cell Carcinoma in China.
Chen J; Hu G; Chen Z; Wan X; Tan C; Zeng X; Cheng Z
Clin Drug Investig; 2019 Oct; 39(10):931-938. PubMed ID: 31250401
[TBL] [Abstract][Full Text] [Related]
20. A case of acute lymphocytic gastritis related to treatment with pembrolizumab for metastatic urothelial carcinoma.
Fukiishi Y; Fukuhara H; Kurano Y; Shugimoto H; Yamashita E; Karasima T; Inoue K
IJU Case Rep; 2023 Mar; 6(2):128-132. PubMed ID: 36874988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
